Literature DB >> 30912356

[Development and application of monoclonal antibodies anti-human lipoprotein-associated phospholipase A2].

Wen Xu1, Zhaoxin Lu1, Lin Cao1.   

Abstract

The aim of this study is to prepare monoclonal anti-human Lp-PLA2 antibodies, and establish a rapid and accurate immunochromatographic Lp-PLA2 assay used in community medical institution. The gene sequence of human Lp-PLA2 was obtained from NCBI to construct the expression plasmid. Lp-PLA2 protein expressed in CHO-K1 cells was used to immune BALB/c mice. The monoclonal antibodies were produced in mouse ascites after hybridoma cells screening. Antibodies were evaluated by SDS-PAGE, ELISA and other methods. The Lp-PLA2 test strip was prepared based on sandwich method and evaluated with the portable detection instrument. The affinity of the paired antibodies, PLA1 and PLA5, both reached 1×10⁻⁸. The antibody subclass was IgG1. Both antibodies recognized the Lp-PLA2 protein in the blood specifically. The Lp-PLA2 test strip was prepared based on sandwich method, with linear range of 20-2000 ng/mL. The Lp-PLA2 test strip correlated well with the diaDexus ELISA test kit. In conclusion, the paired antibodies were successfully prepared with high affinity and specificity. The immunochromatographic test of Lp-PLA2 provided a fast and accurate method to detect the concentration of Lp-PLA2 in blood sample for clinical use in the community medical institution and could contribute to the management of cardiovascular diseases.

Entities:  

Keywords:  atherosclerosis; eukaryotic expression; immunochromatography; lipoprotein-associated phospholipase A2; monoclonal antibody

Mesh:

Substances:

Year:  2019        PMID: 30912356     DOI: 10.13345/j.cjb.180320

Source DB:  PubMed          Journal:  Sheng Wu Gong Cheng Xue Bao        ISSN: 1000-3061


  1 in total

1.  Preparation of highly specific monoclonal antibodies against SARS-CoV-2 nucleocapsid protein and the preliminary development of antigen detection test strips.

Authors:  Chengzuo Xie; Haojie Ding; Jianzu Ding; Yangji Xue; Shaohong Lu; Hangjun Lv
Journal:  J Med Virol       Date:  2021-12-21       Impact factor: 20.693

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.